Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Payables: 2020-2024

Historic Payables for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $2.5 million.

  • Caribou Biosciences' Payables rose 40.68% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 10.64%. This contributed to the annual value of $2.5 million for FY2024, which is 20.64% down from last year.
  • Per Caribou Biosciences' latest filing, its Payables stood at $2.5 million for FY2024, which was down 20.64% from $3.1 million recorded in FY2023.
  • Caribou Biosciences' 5-year Payables high stood at $4.0 million for FY2021, and its period low was $1.1 million during FY2022.
  • Moreover, its 3-year median value for Payables was $2.5 million (2024), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Caribou Biosciences' Payables crashed by 71.28% in 2022, and later surged by 172.25% in 2023.
  • Caribou Biosciences' Payables (Yearly) stood at $2.6 million in 2020, then skyrocketed by 53.40% to $4.0 million in 2021, then plummeted by 71.28% to $1.1 million in 2022, then skyrocketed by 172.25% to $3.1 million in 2023, then fell by 20.64% to $2.5 million in 2024.